{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0004986,73,MONDO:0004986,198,-1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0004986","source":"MONDO:0004986|urinary bladder carcinoma","targets":["NCT00365508|Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking|COMPLETED|PHASE4|INTERVENTIONAL","NCT00666978|Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking|COMPLETED|PHASE4|INTERVENTIONAL","NCT00785694|Recurrence of Bladder Cancer After Transurethral Resection With Hexvix|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT02443844|Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03063255|Comparison of Obturator Nerve Blockade and Neuromuscular Blockade|COMPLETED|PHASE4|INTERVENTIONAL","NCT03138967|Investigation of Sugammadex in Outpatient Urological Procedures|COMPLETED|PHASE4|INTERVENTIONAL","NCT03147586|Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03147599|Mebeverine For 1st Year Daytime And Nocturnal Incontinence After Orthotopic W-Ileal Neobladders|COMPLETED|PHASE4|INTERVENTIONAL","NCT03174912|In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?|COMPLETED|PHASE4|INTERVENTIONAL","NCT03274284|Chemoradiotherapy for Recurrent T1G3 Bladder Cancer|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03348969|Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03790384|Sequential Combination Therapy in Bladder Cancer|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03831321|The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy|UNKNOWN|PHASE4|INTERVENTIONAL","NCT04502095|Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy|COMPLETED|PHASE4|INTERVENTIONAL","NCT04532606|Impact of Remimazolam on Prognosis After Bladder Cancer Surgery|RECRUITING|PHASE4|INTERVENTIONAL","NCT05488353|A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT06390111|A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT06548438|The Impact of PDD During TURB for NMIBC|NOT_YET_RECRUITING|PHASE4|INTERVENTIONAL","NCT06764095|Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial|RECRUITING|PHASE4|INTERVENTIONAL","NCT00002490|Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00002990|Surgery and BCG in Treating Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003376|Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003623|High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003701|Combination Chemotherapy in Treating Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003725|Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00003779|Biological Therapy in Treating Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003814|Eflornithine in Treating Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00003824|S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT00004154|Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00005047|4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT00006034|Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00006124|Celecoxib in Treating Patients With Bladder Cancer|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00014274|Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00014534|Combination Chemotherapy in Treating Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00022191|Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00024349|Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00028756|Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium|COMPLETED|PHASE3|INTERVENTIONAL","NCT00033436|Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00042887|Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT00052637|Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00054626|Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00146276|Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00233402|Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy|COMPLETED|PHASE3|INTERVENTIONAL","NCT00237575|Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT00315237|Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract|COMPLETED|PHASE3|INTERVENTIONAL","NCT00352079|BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT00384891|Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT00389155|First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT00412971|A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00445601|S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00461591|Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00553124|Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00553345|Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT00598806|Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)|COMPLETED|PHASE3|INTERVENTIONAL","NCT00622973|USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases|COMPLETED|PHASE3|INTERVENTIONAL","NCT00729287|Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00867347|Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT00949455|A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT00974818|Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients|TERMINATED|PHASE3|INTERVENTIONAL","NCT01076387|Randomized Trial Comparing Robotic and Open Radical Cystectomy|COMPLETED|PHASE3|INTERVENTIONAL","NCT01082510|Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01087268|Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01094964|Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01284205|First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT01316874|Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT01410565|Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer|TERMINATED|PHASE3|INTERVENTIONAL","NCT01438112|Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT01442519|Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT01469221|Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)|TERMINATED|PHASE3|INTERVENTIONAL","NCT01475266|Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)|TERMINATED|PHASE2/PHASE3|INTERVENTIONAL","NCT01542567|Efficacy of Diclofenac BCG Irrigations|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01627197|Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT01675219|Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)|UNKNOWN|PHASE3|INTERVENTIONAL","NCT01734798|Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT01812369|Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer|COMPLETED|PHASE3|INTERVENTIONAL","NCT01869413|Tranexamic Acid During Cystectomy Trial (TACT)|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02074189|Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT02145871|A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy|COMPLETED|PHASE3|INTERVENTIONAL","NCT02302807|A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]|COMPLETED|PHASE3|INTERVENTIONAL","NCT02355886|Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy|COMPLETED|PHASE2/PHASE3|INTERVENTIONAL","NCT02438852|Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT02449239|Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG|COMPLETED|PHASE3|INTERVENTIONAL","NCT02471495|RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT02560584|A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting|COMPLETED|PHASE3|INTERVENTIONAL","NCT02563561|A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)|TERMINATED|PHASE3|INTERVENTIONAL","NCT02660190|Photodynamic Diagnosis (PDD) in Flexible Cystoscopy|COMPLETED|PHASE3|INTERVENTIONAL","NCT02948543|Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT02951078|A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT02951325|Bladder Cancer Adjuvant Radiotherapy Trial|ACTIVE_NOT_RECRUITING|PHASE3|INTERVENTIONAL","NCT03022825|QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer|ACTIVE_NOT_RECRUITING|PHASE2/PHASE3|INTERVENTIONAL","NCT03193788|Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy|UNKNOWN|PHASE3|INTERVENTIONAL","NCT03216525|Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol|RECRUITING|PHASE3|INTERVENTIONAL","NCT03224182|A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)|TERMINATED|PHASE3|INTERVENTIONAL","NCT03296306|Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma|UNKNOWN|PHASE3|INTERVENTIONAL","NCT03298958|Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer|WITHDRAWN|PHASE3|INTERVENTIONAL","NCT03335059|Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.|TERMINATED|PHASE3|INTERVENTIONAL","NCT03427034|Assessment of BladderLight SurvEILlance|UNKNOWN|PHASE2/PHASE3|INTERVENTIONAL","NCT03474107|A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)|COMPLETED|PHASE3|INTERVENTIONAL","NCT03664869|Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer|UNKNOWN|PHASE3|INTERVENTIONAL","NCT03718754|En-bloc vs Conventional Resection of Primary Bladder Tumor|COMPLETED|PHASE3|INTERVENTIONAL"]}]}